Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EPS (Basic): 2014-2025

Historic EPS (Basic) for vTv Therapeutics (VTVT) over the last 11 years, with Sep 2025 value amounting to -$1.08.

  • vTv Therapeutics' EPS (Basic) fell 22.73% to -$1.08 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.27, marking a year-over-year increase of 27.81%. This contributed to the annual value of -$3.20 for FY2024, which is 67.04% up from last year.
  • As of Q3 2025, vTv Therapeutics' EPS (Basic) stood at -$1.08, which was down 17.39% from -$0.92 recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' EPS (Basic) ranged from a high of -$0.01 in Q2 2021 and a low of -$9.78 during Q4 2022.
  • Over the past 3 years, vTv Therapeutics' median EPS (Basic) value was -$1.08 (recorded in 2025), while the average stood at -$1.44.
  • The largest annual percentage gain for vTv Therapeutics' EPS (Basic) in the last 5 years was 85.71% (2021), contrasted with its biggest fall of 27,400.00% (2021).
  • Quarterly analysis of 5 years shows vTv Therapeutics' EPS (Basic) stood at -$8.19 in 2021, then decreased by 19.41% to -$9.78 in 2022, then skyrocketed by 82.92% to -$1.67 in 2023, then surged by 70.06% to -$0.50 in 2024, then declined by 22.73% to -$1.08 in 2025.
  • Its EPS (Basic) stands at -$1.08 for Q3 2025, versus -$0.92 for Q2 2025 and -$0.77 for Q1 2025.